PTC Therapeutics, Inc.
(NASDAQ : PTCT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Loading PTCT News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.04%68.550.9%$505.54m
AMGNAmgen Inc.
0.37%163.321.1%$461.64m
BIIBBiogen Inc.
-1.94%271.211.2%$423.43m
CELGCelgene Corporation
0.07%124.051.2%$383.45m
REGNRegeneron Pharmaceuticals, Inc.
5.97%388.492.7%$332.95m
ALXNAlexion Pharmaceuticals, Inc.
0.69%127.781.9%$250.96m
INCYIncyte Corporation
0.09%124.282.6%$247.36m
VRTXVertex Pharmaceuticals Incorporated
0.75%118.301.9%$235.75m
ILMNIllumina, Inc.
0.61%184.863.5%$200.54m
TSROTESARO, Inc.
0.67%147.5914.7%$130.72m
NBIXNeurocrine Biosciences, Inc.
-0.36%53.405.3%$114.24m
BMRNBioMarin Pharmaceutical Inc.
-0.40%95.884.5%$113.09m
KITEKite Pharma, Inc.
-0.68%82.0816.6%$94.29m
AAgilent Technologies, Inc.
-0.70%55.041.5%$93.33m
SRPTSarepta Therapeutics, Inc.
4.44%36.2619.8%$82.73m

Company Profile

PTC Therapeutics, Inc. engages in the discovery, development, and commercialization of orally administered, small molecule therapeutics targeting an area of RNA biology. Its preclinical and discovery programs are focused on the development of new treatments for multiple therapeutic areas, including neuromuscular disease, oncology and infectious disease. It product, candidate ataluren, is used for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. The company was founded by Allan S. Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.